EWTX Q2 2023 Earnings — Edgewise Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

EWTXEdgewise Therapeutics, Inc.

$3B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$25M

Net Income

-$21M

EPS (Diluted)

$-0.34

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$331M

Total Liabilities

$19M

Stockholders' Equity

$311M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$25M	-$16M	-53.7%
Net Income	-$21M	-$16M	-33.6%